Fast-growing BeiGene blueprints 42-acre R&D and manufacturing campus in the US, with plans to hire 'hundreds'
BeiGene has made its presence in the US known with the FDA approval of its oncology treatment two years ago, and its five offices across the country. Tuesday, the company announced that it will add a sixth location, this time an R&D and manufacturing campus, in Hopewell, NJ, nearly 60 miles away from its other office in the region.
The new campus will be built on a 42-acre site. The facility will include commercial-stage manufacturing, clinical R&D and the “BeiGene Center for Pharmacovigilance Innovation.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.